La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Ocugen Performance dei guadagni passati

Il passato criteri di controllo 0/6

Gli utili di Ocugen sono diminuiti a un tasso medio annuo di -31.8%, mentre il settore Biotechs ha visto gli utili crescere a un tasso medio annuo di 11.8%. I ricavi sono cresciuti diminuire a un tasso medio annuo di 22.6%.

Informazioni chiave

-31.8%

Tasso di crescita degli utili

68.9%

Tasso di crescita dell'EPS

Biotechs Crescita del settore	14.2%
Tasso di crescita dei ricavi	-22.6%
Rendimento del capitale proprio	-129.3%
Margine netto	n/a
Ultimo aggiornamento sui guadagni	30 Sep 2023

Aggiornamenti sulle prestazioni recenti

Recent updates

Ripartizione dei ricavi e delle spese

Come Ocugen guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.

Storia dei guadagni e delle entrate

BUL:2H51 Ricavi, spese e utili (USD Millions )
Data	Guadagni	Spese G+A	Spese di R&S
30 Sep 23	-76	34	0
30 Jun 23	-83	33	0
31 Mar 23	-80	33	0
31 Dec 22	-81	35	0
30 Sep 22	-74	36	0
30 Jun 22	-63	32	0
31 Mar 22	-69	29	0
31 Dec 21	-58	23	0
30 Sep 21	-48	18	0
30 Jun 21	-47	15	0
31 Mar 21	-38	10	0
31 Dec 20	-34	8	0
30 Jun 20	-30	8	1
31 Mar 20	-18	7	-3
31 Dec 19	-20	6	0
30 Sep 19	-39	6	9
30 Jun 19	-18	6	4
31 Mar 19	-19	6	11
31 Dec 18	-18	6	10

Guadagni di qualità: 2H51 al momento non è redditizia.

Margine di profitto in crescita: 2H51 al momento non è redditizia.

Flusso di cassa libero e analisi degli utili

Analisi della crescita degli utili nel passato

Andamento degli utili: 2H51 non è redditizia e le perdite sono aumentate negli ultimi 5 anni a un tasso pari a 31.8% all'anno.

Accelerare la crescita: Impossibile confrontare la crescita degli utili di 2H51 nell'ultimo anno con la sua media quinquennale poiché al momento non è redditizia

Guadagni vs Settore: 2H51 non è redditizia, il che rende difficile confrontare la crescita dei suoi utili dell'anno passato con il settore Biotechs ( -0.08% ).

Rendimento del capitale proprio

ROE elevato: 2H51 ha un Return on Equity negativo ( -129.33% ), in quanto al momento non è redditizio.

Ocugen Performance dei guadagni passati

Il passato criteri di controllo 0/6

Informazioni chiave

Aggiornamenti sulle prestazioni recenti

Ocugen, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Ocugen, Inc. to Report Q4, 2023 Results on Apr 02, 2024

Ocugen, Inc. to Report Q3, 2023 Results on Nov 09, 2023

Ocugen, Inc. to Report Q2, 2023 Results on Aug 21, 2023

Ocugen, Inc. to Report Q4, 2022 Results on Feb 28, 2023

Ocugen, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Recent updates

Ocugen, Inc. Announces FDA Approval of Expanded Access Program for Patients with Retinitis Pigmentosa

Ocugen, Inc. has completed a Follow-on Equity Offering in the amount of $35 million.

Ocugen, Inc. has completed a Follow-on Equity Offering in the amount of $35 million.

Ocugen, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Ocugen, Inc. Announces Completion of Dosing in Subjects with Geographic Atrophy Secondary to dAMD in High-Dose Cohort of Phase 1/2 Armada Clinical Trial of OCU410 —A Novel Modifier Gene Therapy

Ocugen, Inc. Announces Data and Safety Monitoring Board Approves Enrollment in High Dose Cohort 3 in GARDian Study for Stargardt Disease

Ocugen, Inc. Announces First Patient Dosed in Phase 3 Limelight Clinical Trial for Ocu400—First Gene Therapy in Phase 3 with A Broad Retinitis Pigmentosa Indication

Law Offices of Howard G. Smith Alleges Lawsuit Against Ocugen, Inc

Ocugen, Inc. Announces Positive Outcome of the Data and Safety Monitoring Board Review for its Phase 1/2 ArMaDa Clinical Trial for OCU410

Ocugen, Inc., Annual General Meeting, Jun 28, 2024

Ocugen Announces Dosing Completion of Subjects with Stargardt Disease in Cohort 2 of Phase 1/2 GARDian Clinical Trial of OCU410ST—A Modifier Gene Therapy

Ocugen, Inc. Announces Ocu400 Modifier Gene Therapy Phase 1/2 Data Presentation At Retinal Cell and Gene Therapy Innovation Summit 2024

Ocugen, Inc. Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 2 of Phase 1/2 ArMaDa Clinical Trial of OCU410 --A Modifier Gene Therapy

Rosen Law Firm Files Securities Class Action Lawsuit on Behalf of Ocugen, Inc

Ocugen, Inc. Announces U.S. FDA Clearance of IND Amendment to Initiate OCU400 Phase 3 Clinical Trial

Ocugen, Inc. Announces Positive Data and Safety Monitoring Board Review and Initiation of Enrollment in Medium Dose for Ocu410--A Modifier Gene Therapy-- in Phase 1/2 Armada Study for Geographic Atrophy

Ocugen Provides Business Update

Ocugen, Inc. to Report Q4, 2023 Results on Apr 02, 2024

Ocugen, Inc. Appoints Huma Qamar as Chief Medical Officer

Ocugen, Inc. Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 1 of Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410

Ocugen, Inc. Announces Dosing Completion of Subjects with Stargardt in Cohort 1 of Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410ST

Ocugen, Inc. Announces Bob Smith Joins Business Advisory Board

Ocugen, Inc. Gains FDA Alignment on Key Aspects of OCU400 —Modifier Gene Therapy—Pivotal Phase 3 Study Design

Ocugen, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410—Modifier Gene Therapy—For Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

Ocugen, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410ST --Modifier Gene Therapy-- for Stargardt Disease

Ocugen, Inc. to Report Q3, 2023 Results on Nov 09, 2023

Ocugen, Inc. Announces Ocugen Mucosal Vaccine Candidate OCU500 Selected by NIH NIAID Project NextGen for Inclusion in Clinical Trials

Ocugen, Inc. Appoints Connie Collingsworth to the Business Advisory Board

Ocugen, Inc. Announces Executive Changes

Ocugen, Inc. Announces Positive Clinical Study Update from the Phase 1/2 Trial of Ocu400, A Modifier Gene Therapy Product Candidate, for the Treatment of Retinitis Pigmentosa and Leber Congenital Amaurosis

Ocugen, Inc. to Report Q2, 2023 Results on Aug 21, 2023

Ocugen, Inc. announced delayed 10-Q filing

Ocugen, Inc. Announces Business Advisory Board

Ocugen, Inc. has completed a Follow-on Equity Offering in the amount of $15 million.

Ocugen, Inc. has completed a Follow-on Equity Offering.

No longer forecast to breakeven

Ocugen, Inc. to Report Q4, 2022 Results on Feb 28, 2023

Ocugen, Inc. Appoints Quan A. Vu as Chief Business Officer

Ocugen, Inc. Announces Positive Top-Line Data for COVID-19 Vaccine Candidate COVAXIN™ (BBV152) in Phase 2/3 Immuno-Bridging and Broadening Study: Both Co-Primary Endpoints Met

Forecast to breakeven in 2025

Ocugen, Inc Announces Update on OCU400 Phase 1/2 Clinical Trial Targeting Retinitis Pigmentosa and Leber Congenital Amaurosis

High number of new directors

Ocugen, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Ocugen Announces Completion of Dosing in OCU400 Phase 1/2 Cohort 2

Ocugen, Inc. Announces Publication of Comprehensive Review of BBV152 in Frontiers in Immunology

Ocugen, Inc. Announces Board Changes

No longer forecast to breakeven

Ocugen, Inc. to Report Q2, 2022 Results on Aug 05, 2022

Ocugen, Inc. Announces Publication of Positive Results of Covid-19 Vaccine Trial for Children 2 18 in the Lancet Infectious Diseases

Ocugen, Inc. Announces New Cell Therapy Program Following FDA Regenerative Medicine Advanced Therapy (RMAT) Recognition

Ocugen, Inc. Announces New Cell Therapy Program Following FDA Regenerative Medicine Advanced Therapy (RMAT) Recognition

Ocugen Announces FDA Removes Clinical Hold on Phase 2/3 Clinical Trial for Covaxin (Bbv152)

Forecast breakeven date pushed back to 2023

Ocugen, Inc. to Report Q1, 2022 Results on May 06, 2022

High number of new and inexperienced directors

Ocugen, Inc. Announces Positive DSMB Recommendation for OCU400-101 Clinical Trial

Ocugen, Inc. Provides Update on its Phase 2/3 Study of COVAXIN™ (BBV152)

Ocugen, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial for Gene Therapy Candidate OCU400 to Treat Inherited Retinal Degeneration

Ocugen, Inc. Announces Resignation of Sanjay S. Subramanian as Chief Financial Officer

Ocugen, Inc. Provides Update on its COVAXIN™ Pediatric (2-18) Emergency Use Authorization Request

Forecast breakeven date pushed back to 2023

Ocugen, Inc. has completed a Follow-on Equity Offering in the amount of $53.5 million.

Ocugen, Inc. has completed a Follow-on Equity Offering in the amount of $53.5 million.

Ocugen, Inc. Announces U.S. FDA Lifts Clinical Hold on the Submission of its Investigational New Drug Application for Its COVID-19 Vaccine Candidate COVAXIN™ (BBV152)

Ocugen, Inc. (NasdaqCM:OCGN) signed a non-binding letter of intent to acquire a manufacturing site in Belleville, Ontario from Liminal BioSciences Inc. (DB:PJ2N).

Ocugen, Inc. and Bharat Biotech Announce Results from a Study Conducted at Emory University

Ocugen, Inc. Announces COVAXIN (BBV152) Booster Dose Study Demonstrates Robust Immune Responses and Long-Term Safety

Ocugen Partner, Bharat Biotech, Announces Positive Immunogenicity and Safety Data From COVAXIN (BBV152), COVID-19 Candidate Vaccine

Ocugen, Inc. announces New Data Suggest COVAXIN™ (BBV152) Vaccine Candidate Generates Robust Immune Memory to COVID-19 and Variants of Concern for At Least Six Months After Vaccination